ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Identification and Mechanisms of Osteocyte Subsets Involved in the Pathological Progression of Osteoporosis.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Identification and Mechanisms of Osteocyte Subsets Involved in the Pathological Progression of Osteoporosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Osteocytes are the most abundant cell type in bone. However, the detailed functions of osteocyte subsets in osteoporosis have remained obscure. In this study, it is aimed to investigate the impact of osteocyte subset heterogeneity on the pathological process of osteoporosis and new potential molecular mechanisms. Six osteocyte subsets are identified in mouse bones by single-cell sequencing. Among them, the epidermal growth factor receptor (Egfr)+ interleukin-1 receptor type I (Il1r1)+ Semaphorin 5a (Sema5a)+osteocyte subpopulation (bone homeostasis regulatory osteocytes, BHR-Ocys) played a key role in the maintenance of bone homeostasis by regulating osteoblasts and osteoclasts. The data confirm that the increased proportion of BHR-Ocys contributes to bone loss in the postmenopausal osteoporotic mice. Mechanistically, Sema5a derived from BHR-Ocys binds to the osteoclast receptor protein Plexin A1 (Plxna1), thereby activating the phosphatidylinositol-3 kinase/protein kinase B/myelocytomatosis oncogen (PI3K/AKT/Myc) signaling pathway, leading to active osteoclast-mediated bone resorption. In conclusion, BHR-Ocys is a key cell subpopulation in the regulation of bone homeostasis. The Sema5a-Plxna1 axis is an important mechanism for BHR-Ocys to regulate osteoclast differentiation. The study provides new insights into the role and mechanism of osteocytes in the regulation of bone homeostasis and identifies new targets for the prevention and treatment of osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.